AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 27 |
Market Cap | 2.12B |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -15.87 |
PE Ratio (ttm) | -1.76 |
Forward PE | n/a |
Analyst | Buy |
Ask | 29.8 |
Volume | 424,605 |
Avg. Volume (20D) | 651,545 |
Open | 28.92 |
Previous Close | 28.68 |
Day's Range | 27.70 - 28.92 |
52-Week Range | 25.77 - 50.23 |
Beta | undefined |
About CGON
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-...
Analyst Forecast
According to 9 analyst ratings, the average rating for CGON stock is "Buy." The 12-month stock price forecast is $65, which is an increase of 132.89% from the latest price.
1 month ago · seekingalpha.com
CG Oncology: Positive Phase 3 Outcome Could Lead To BLA Of CretostimogeneCG Oncology, Inc. reported positive phase 3 BOND-003 results for Cretostimogene in treating BCG-unresponsive NMIBC, presented at the SUO 25th Annual Meeting. The company aims to use Cretostimogene as ...